A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma

Journal of Thoracic Oncology

Volumn 11, Issue 10, 2016, Pages 1690-1700

  Reckamp, Karen L ^a   Melnikova, Vladislava O ^b   Karlovich, Chris ^c   Sequist, Lecia V ^d   Camidge, D Ross ^e   Wakelee, Heather ^f   Perol, Maurice ^g   Oxnard, Geoffrey R ^h   Kosco, Karena ^b   Croucher, Peter ^b   Samuelsz, Errin ^b   Vibat, Cecile Rose ^b   Guerrero, Shiloh ^b   Geis, Jennifer ^c   Berz, David ^a,i   Mann, Elaina ^c   Matheny, Shannon ^c   Rolfe, Lindsey ^c   Raponi, Mitch ^c   Erlander, Mark G ^b   Gadgeel, Shirish ^j   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Trovagene Inc   (United States)

^c Clovis Oncology Inc   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g HOSPICES CIVILS DE LYON   (France)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ Beverly Hills Cancer Center   (United States)

^j KARMANOS CANCER INSTITUTE   (United States)

more..

Author keywords

Circulating tumor DNA; EGFR mutations; NSCLC; T790M; Urine

Indexed keywords

ROCILETINIB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; EGFR GENE; EXON; FEASIBILITY STUDY; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONITORING; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; URINE; BLOOD; DOUBLE BLIND PROCEDURE; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84991067919     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.05.035     Document Type: Article

References (35)

1. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011;17:1169-1180.
2. Douillard JY, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulatingfree tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9:1345-1353.
3. Accordino MK, Wright JD, Buono D, et al. Trends in use and safety of image-guided transthoracic needle biopsies in patients with cancer. J Oncol Pract. 2015;11: e351-359.
4. Levy BP, Chioda MD, Herndon D, et al. Molecular testing for treatment of metastatic non-small cell lung cancer: how to implement evidence-based recommendations. Oncologist. 2015;20:1175-1181.
5. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8: 823-859.
6. Spicer J, Tischer B, Peters M. EGFR mutation testing and oncologist treatment choice in advanced NSCLC: global trends and differences. Ann Oncol. 2015;26 (suppl):i57-i61.
7. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFRTKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247.
8. Yoon HJ, Lee HY, Lee KS, et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology. 2012;265:939-948.
9. Piotrowska Z, Niederst MJ, Karlovich CA, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 2015;5:713-722.
10. Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010;16: 5489-5498.
11. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32: 579-586.
12. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014;6, 224ra224.
13. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2007;14: 985-990.
14. Karlovich C, Goldman JW, Sun JM, et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). Clin Cancer Res. 2016;22:2386-2395.
15. Marchetti A, Palma JF, Felicioni L, et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol. 2015;10:1437-1443.
16. Mok T, Wu YL, Lee JS, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015;21:3196-3203.
17. Sausen M, Phallen J, Adleff V, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015;6:7686.
18. Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a crossplatform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015;90:509-515.
19. Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795-801.
20. Couraud S, Vaca-Paniagua F, Villar S, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res. 2014;20:4613-4624.
21. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199-1209.
22. Karachaliou N, Mayo-de las Casas C, Queralt C, et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol. 2015;1:149-157.
23. Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20:1698-1705.
24. Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016;2:1014-1022.
25. Botezatu I, Serdyuk O, Potapova G, et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem. 2000;46:1078-1084.
26. Lichtenstein AV, Melkonyan HS, Tomei LD, et al. Circulating nucleic acids and apoptosis. Ann N Y Acad Sci. 2001;945:239-249.
27. Su YH, Wang M, Brenner DE, et al. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn. 2004;6: 101-107.
28. Su YH, Wang M, Aiamkitsumrit B, et al. Detection of a Kras mutation in urine of patients with colorectal cancer. Cancer Biomark. 2005;1:177-182.
29. Hyman DM, Diamond EL, Vibat CR, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015;5:64-71.
30. Janku F, Vibat CR, Kosco K, et al. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget. 2014;5: 3607-3610.
31. Su Y-H, Song J, Wang Z, et al. Removal of highmolecular-weight DNA by carboxylated magnetic beads enhances the detection of mutated K-ras DNA in urine. Ann N Y Acad Sci. 2008;1137:82-91.
32. Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372:1700-1709.
33. Chan KC, Leung SF, Yeung SW, et al. Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients. Clin Cancer Res. 2008;14:4809-4813.
34. Melkonyan HS, Feaver WJ, Meyer E, et al. Transrenal nucleic acids: from proof of principle to clinical tests. Ann N Y Acad Sci. 2008;1137:73-81.
35. Tsui NB, Jiang P, Chow KC, et al. High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. PLoS One. 2012;7:e48319.